NETSOL Technologies reports record fiscal 2026 revenue and full-year profitability, exceeding guidance

NetSol (NTWK) reported fiscal 2026 revenue of $74.4M, up 12.5% YoY, exceeding guidance. Q4 revenue was $20.7M, a quarterly record. Operating income rose 98.4% to $6.9M. Cash increased 56.3% to $27.1M. Management guided FY2027 revenue growth of 13-16% and adjusted EBITDA of $10.5M-$11.4M. Risks include non-controlling interests and quarterly variability.

Today’s technology M&A activity includes acquisitions by Amphenol, Net at Work, and Zedcrest Group, expanding compliance testing technologies, managed IT and cybersecurity services, and cross-border payment infrastructure. Amphenol Acquires Wilder Technologies Amphenol announced the acquisition of Wilder Technologies, a U.S.-based manufacturer of compliance testing equipment for high-speed data communications and optical interconnects.

Tesla reported Q3 earnings, highlighting improved automotive gross margins (18.3%), reduced capex forecasts (~$20B), and progress on Robotaxi rollout. CEO Elon Musk noted strong demand. CFO Vaibhav Taneja addressed cash flow concerns, easing investor worries. The company remains on track with its full self-driving (FSD) software v15 release, expected in Q1 or Q2 2024.

Bank Bradesco SA (BBD) reported Q3 2026 earnings with resilient profit growth but faced pressures on net interest margin (NIM) due to corporate mix and higher cost of risk. Over-90-day NPLs rose to 4.6%, driven by FGI/FGO portfolios and John Deere Bank seasonality. CEO Marcelo Noronha expects NIM improvement in Q4 2026 but acknowledges macroeconomic challenges. The bank is reducing exposure to high-risk personal loans and credit cards.

Dr. Reddy's Laboratories reported a 1.5% year-over-year revenue decline, driven by lower lenalidomide sales and declines in North America, Europe, and PSAI businesses. The company expects margins to improve with new products and business mix, targeting a 55% gross margin. Semaglutide relaunch is planned for November 2026, and abatacept biosimilar approval is expected by December 2026.

Barclays reported a 12% rise in Q3 pre-tax profit to £2.3bn, driven by revenue growth and lower impairment charges. The bank announced a £500m share buyback and plans to cut 5,000 jobs. Revenue increased 3% to £7.4bn, while earnings per share rose 18%. Trading revenues showed mixed results, with equities up 47% and fixed income down 19%. Shares fell over 2.5% post-announcement.